February 2015
|
Class Review |
Oral Oncological Agents/Prostate I & II |
December 2014
Belsomra - Solicitation Cancelled
|
Class Review |
Transmucosal Immediate Rlease Fentanyl |
Class Review |
Pulmonary Aterial Hypertension Agents |
Designated Newly Approved Drugs |
Zonitivity, Hetlioz, Belsomra, Jardiance, Esomeprasole Strontium, Stendra |
May 2015
|
Class Review |
Newer Oral Anticoagulants and Warfarin |
March 2015 |
Class Review |
Hepatitis Antivirals (Hepatitis C) |
Designated Newly Approved Drugs |
Belsomra, Plegridy, Diclegis |
August 2015 |
Class Review |
Diabetes Non-Insulin (GLP-1 Receptor Agonists) |
June 2015
|
Class Review |
Diabetes Non-Insulin (SGLT-2 Inhibitors) |
Class Review |
Narcotic Analgesics - Long Acting |
Class Review |
Oncological Agents - CML Drugs |
Designated Newly Approved Drugs |
Incruse Ellipta, Cosentyx |
November 2015 |
Class Review |
Attention Deficit Hyperactivity Disorder - Stimulants |
October 2015
|
Class Review |
Antirheumatics - Injectable Methorexate |
Class Review |
Gastrointestinal-2 Agents - Miscellaneous |
Class Reveiw |
Acne - Isotretinoids |
Designated Newly Approved Drugs |
Namenda XR, Namzaric |